Skip to main content

Fantastic day trade as company phase 3 trial met primary endpoint. Plus, market update 📈 📉

IVERIC bio (ticker: ISEE) announced today positive top line data from their Zimura GATHER2 phase 3 clinical trial.

The ticker was in our focus list, so we were able to get an early start of the day trading action.

Watch this video to get the technicals and what to expect moving forward.

Good trading!


Trading Risk Disclaimer

All the information shared is provided for educational purposes only. Any trades placed upon reliance of SharperTrades, LLC are taken at your own risk for your own account. Past performance is no guarantee. While there is great potential for reward trading stocks, cryptos, commodities, options, forex and other trading securities, there is also substantial risk of loss. All trading operations involve high risks of losing your entire investment. You must therefore decide your own suitability to trade. Trading results can never be guaranteed. SharperTrades, LLC is not registered as an investment adviser with any federal or state regulatory agency. This is not an offer to buy or sell stocks, cryptos, forex, futures, options, commodity interests or any other trading securities.

Popular posts from this blog

Super Micro's Plunge Sparks Concerns Amidst AI Frenzy

JPMorgan Chase Faces Investor Disappointment Despite Strong Q1 Performance